FOR ELIGIBLE COMMERCIALLY INSURED PATIENTS
More support for your patients:
Starting Taltz has never been easier
More commercial insurance plans than ever are offering Taltz as the preferred IL-17A antagonist1
Access regardless of treatment history or formulary requirements for as little as $5 or $25 per month, for up to 3 years.* Governmental beneficiaries excluded, terms and conditions apply.
For commercially insured patients, after the treatment decision is made:
NEW TOOLS for patients to get started
Prior authorization (PA) assistance available through CoverMyMeds for patients where a PA request is required.
Text to activate
Text "Taltz" to 55900 to access a savings card.
Complete a Taltz Together Enrollment Form or send the prescription directly to an Enhanced Network Specialty Pharmacy to start your patients on Taltz.
Contact your sales representative for local plan information and patient support resources.
FOR ELIGIBLE COMMERCIALLY INSURED PATIENTS
Access Taltz through a specialty pharmacy that is convenient for patients.
Over 150 specialty pharmacies can dispense Taltz.
To enroll in the Taltz Clear Access Program, the prescription must be sent to Taltz Together or an Enhanced Specialty Pharmacy partner.
Taltz Together can accept a prescription for Taltz via the Taltz Together Enrollment Form.
Enhanced Specialty Pharmacy Partners can accept a prescription for Taltz in 1 of 3 ways:
- Electronic prescription
- Taltz Together Enrollment Form
- Specialty pharmacy enrollment form
If your preferred specialty pharmacy is not included in the Taltz Enhanced Specialty Pharmacy Network , you must submit a completed enrollment form to Taltz Together.
If you have questions, your Taltz sales representative will be able to assist you.
What are the steps to start a patient on Taltz?
Start with a Taltz Together Enrollment Form, which serves as the Taltz prescription
1. Depending on your office workflow, decide where the Taltz prescription will be sent.
Your options include:
A. Send the prescription to Taltz Together directly.
B. Send the prescription to a specialty pharmacy of your choice. You can find the list of the enhanced specialty pharmacy network partners here.
Declare your selection on the Taltz Together Enrollment Form.
2. Complete the Taltz Together Enrollment Form and have your patient sign it.
If the patient leaves the office without signing the enrollment form, have them call Taltz Together or go online at taltz.com to get their Taltz Savings Card.
3. When discussing initiation of Taltz treatment with your patient, be sure to instruct them to answer the phone to schedule Taltz shipment. Remind your patient to call Taltz Together should they have any questions or concerns about access or treatment cost.
4. Fax the Taltz Together Enrollment Form to Taltz Together (1-844-344-8108).
If sending the prescription to a specialty pharmacy, fax the completed Taltz Together Enrollment Form to Taltz Together and the specialty pharmacy.
Other types of support available for your patients
Your patients can now enroll directly in Taltz Together™ with the Lilly Together™ app.
To get started, patients can search for “Lilly Together” in the App Store® or on Google Play™ to download the app. Once signed in, patients can:
- Access their savings card information directly through the app so it's always with them.
- Use symptom tracking to help them understand progress and stay motivated on treatment, and give you a more complete view of their symptom information all in one place the next time you meet.
- Connect with a Companion in Care™ team member for ongoing support.
- Browse helpful resources and hear from other patients on Taltz all inside the app.
Taltz is indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
IMPORTANT SAFETY INFORMATION
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.
Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.
IX HCP ISI 07MAY2020